inclusion criteria: * 1. male or female adult ≥ 18 years of age at the time of giving informed consent. * 2. subject is hospitalized. * 3. sars-cov-2 infection confirmed by pcr or other commercial or public health tests, in any biological sample obtained up to 4 days prior to randomization, or that meets locally accepted criteria for clinical diagnosis of covid-19. * 4. lung involvement confirmed by at least one of the following criteria: 1. radiological infiltrates on imaging test (conventional radiography, computed tomography (ct) or other) 2. in the absence of radiological infiltrates, an spo2 \< 95% without oxygen supporting therapy (breathing ambient air), combined with cough, crackles on physical exam, or an ldh \> 300 u/l with no other cause. * 5. symptom onset ≤ 8 days prior to randomization. * 6. understands and agrees to comply with planned study procedures. * 7. women of childbearing potential must have a negative test for pregnancy (blood or urine) before their inclusion and agree to use an accepted method of contraception for the duration of the study. * 8. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.

inclusion criteria: * 1. male or female adult ≥ 18 years of age at the time of giving informed consent. * 2. subject is hospitalized. * 3. sars-cov-2 infection confirmed by pcr or other commercial or public health tests, in any biological sample obtained up to 4 days prior to randomization, or that meets locally accepted criteria for clinical diagnosis of covid-19. * 4. lung involvement confirmed by at least one of the following criteria: 1. radiological infiltrates on imaging test (conventional radiography, computed tomography (ct) or other) 2. in the absence of radiological infiltrates, an spo2 \< 95% without oxygen supporting therapy (breathing ambient air), combined with cough, crackles on physical exam, or an ldh \> 300 u/l with no other cause. * 5. symptom onset ≤ 8 days prior to randomization. * 6. understands and agrees to comply with planned study procedures. * 7. women of childbearing potential must have a negative test for pregnancy (blood or urine) before their inclusion and agree to use an accepted method of contraception for the duration of the study. * 8. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.

inclusion criteria: 1. male or female adult ≥ 18 years of age at the time of giving informed consent. 2. subject is hospitalized. 3. sars-cov-2 infection confirmed by pcr or other commercial or public health tests, in any biological sample obtained up to 4 days prior to randomization, or that meets locally accepted criteria for clinical diagnosis of covid-19. 4. lung involvement confirmed by at least one of the following criteria: radiological infiltrates on imaging test (conventional radiography, computed tomography (ct) or other) in the absence of radiological infiltrates, an spo2 < 95% without oxygen supporting therapy (breathing ambient air), combined with cough, crackles on physical exam, or an ldh > 300 u/l with no other cause. 5. symptom onset ≤ 8 days prior to randomization. 6. understands and agrees to comply with planned study procedures. 7. women of childbearing potential must have a negative test for pregnancy (blood or urine) before their inclusion and agree to use an accepted method of contraception for the duration of the study. 8. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.

inclusion criteria: 1. male or female adult ≥ 18 years of age at the time of giving informed consent. 2. subject is hospitalized. 3. sars-cov-2 infection confirmed by pcr or other commercial or public health tests, in any biological sample obtained up to 4 days prior to randomization, or that meets locally accepted criteria for clinical diagnosis of covid-19. 4. lung involvement confirmed by at least one of the following criteria: radiological infiltrates on imaging test (conventional radiography, computed tomography (ct) or other) in the absence of radiological infiltrates, an spo2 < 95% without oxygen supporting therapy (breathing ambient air), combined with cough, crackles on physical exam, or an ldh > 300 u/l with no other cause. 5. symptom onset ≤ 8 days prior to randomization. 6. understands and agrees to comply with planned study procedures. 7. women of childbearing potential must have a negative test for pregnancy (blood or urine) before their inclusion and agree to use an accepted method of contraception for the duration of the study. 8. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.

inclusion criteria: - 1. male or female adult ≥ 18 years of age at the time of giving informed consent. - 2. subject is hospitalized. - 3. sars-cov-2 infection confirmed by pcr or other commercial or public health tests, in any biological sample obtained up to 4 days prior to randomization, or that meets locally accepted criteria for clinical diagnosis of covid-19. - 4. lung involvement confirmed by at least one of the following criteria: 1. radiological infiltrates on imaging test (conventional radiography, computed tomography (ct) or other) 2. in the absence of radiological infiltrates, an spo2 < 95% without oxygen supporting therapy (breathing ambient air), combined with cough, crackles on physical exam, or an ldh > 300 u/l with no other cause. - 5. symptom onset ≤ 8 days prior to randomization. - 6. understands and agrees to comply with planned study procedures. - 7. women of childbearing potential must have a negative test for pregnancy (blood or urine) before their inclusion and agree to use an accepted method of contraception for the duration of the study. - 8. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.

inclusion criteria: - 1. male or female adult ≥ 18 years of age at the time of giving informed consent. - 2. subject is hospitalized. - 3. sars-cov-2 infection confirmed by pcr or other commercial or public health tests, in any biological sample obtained up to 4 days prior to randomization, or that meets locally accepted criteria for clinical diagnosis of covid-19. - 4. lung involvement confirmed by at least one of the following criteria: 1. radiological infiltrates on imaging test (conventional radiography, computed tomography (ct) or other) 2. in the absence of radiological infiltrates, an spo2 < 95% without oxygen supporting therapy (breathing ambient air), combined with cough, crackles on physical exam, or an ldh > 300 u/l with no other cause. - 5. symptom onset ≤ 8 days prior to randomization. - 6. understands and agrees to comply with planned study procedures. - 7. women of childbearing potential must have a negative test for pregnancy (blood or urine) before their inclusion and agree to use an accepted method of contraception for the duration of the study. - 8. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.